The present invention relates to high drug load, non-dispersible pharmaceutical compositions comprising iron chelating agents or their pharmaceutically acceptable salts, esters, solvates, polymorphs, enantiomers or mixtures thereof wherein, the pharmaceutical composition comprises more than 60% of Deferasirox by weight with respect to total weight of the pharmaceutical dosage form and exhibits disintegration time in the range of about 2 to about 10 minutes. The invention also relates to a process for preparation of a pharmaceutical dosage form comprising an effective amount of Deferasirox wherein, the dosage form exhibits dissolution profile comparable to the commercially available counterpart (JADENU® oral tablets) after oral administration.
